ARTICLE | Company News
ImmunoGen, Raven deal
April 2, 2001 7:00 AM UTC
Raven will identify targets to treat ovarian cancer and develop monoclonal antibodies against them, and IMGN will develop therapeutic products from the antibodies. IMGN will be responsible for develop...